Citations

Clear

9383 citation(s) found for "Thomas, PS".

Brain atrophy patterns in anti-IgLON5 disease
Yogeshwar, Selina , Bartels, Frederik , Muñiz‐Castrillo, Sergio , Picard, Géraldine , Bernard, E , Ζεκερίδου, Αναστασία , Ringelstein, Marius , Kraft, Andrea , Kovac, Stjepana , Wandinger, Klaus‐Peter , Vries, Juna M. de, Boon, Agnita J.W. , Veenbergen, Sharon , Penner, Loana , Gaig, Carles , Sabater, Lídia , Santamaría, Joan , Prüß, Harald , Lewerenz, Jan , Irani, Sarosh R. , Mignot, Emmanuel , Titulaer, Maarten J. , Ayzenberg, Ilya , Francillard, Aurélie Méneret Isabelle, Renard, Dimitri , Desestret, Virginie, Capet, Nicolas , Davion, Jean‐Baptiste , Boucher, Julie, Combres, Helene, Rafiq, Marie , Bonneville, Fabrice , Cumin, Marina, Soulages, Antoine , Compoint, Mathilde, Moulin, Maximilien , Berling, Édouard , Garrigues, Eve, Chanson, Marine, Bourg, Veronique , Giordana, Caroline, Benoit, Jeanne , Flabeau, Olivier, Derivoyre, Emmanuelle, Ryckewaert, Gilles, Alberto, Tifanie, Carrière, Nicolas , Mostoufizadehs, Sohrab, Barbay, Mélanie , Bénaiteau, Marie , Sellal, François , Casez, Olivier, Bruel, Cédric , Kalifa, L G, Rusu, Elena Camelia, Demortière, Sarah , Maarouf, Adil, Wang, Adrien , Brasset, Adelaide, Attal, Arthur, Demourant, Céline, Houéto, Jean‐Luc , Brueggemann, Norbert, Dargvainiene, Justina , Oy, Ulrich Hofstadt‐van , Nagel, Michael , Urbanek, Christian, Schroeder, Ina, Schramm, Peter , Tonner, Silke, Seitz, Caspar , Tschernatsch, Marlene , Chung, Ha‐Yeun , Wickel, Jonathan , Schoeberl, Florian, Macher, Stefan , Simabukuro, Mateus Mistieri , Zittel-Dirks, Simone, Wildemann, Brigitte , Kothaj, Ján, Ordás, Carlos , Angstwurm, Klemens , Tomás, Ángela Milán, Bastida, Antonio Martin, Quintas, Sonia , Kimura, Akio , Akira, Takekoshi, Scheller-Nissen, Mette, Hartmann, Christian, Bastiaansen, Danielle, Steenhoven, Robin van, Schwichtenberg, Katia , Yogeshwar, Selina M , Grüter, Thomas , Muñiz-Castrillo, Sergio , Melzer, Nico , Leypoldt, Frank , Pittock, S J , Höftberger, Romana , Howe, Charles L , Irani, Sarosh R , Mignot, Emmanuel , Honnorat, Jérôme , Finke, Carsten , Titulaer, Maarten J , Crijnen, Y S , Heidbreder, Anna , Geis, Christian , Blaabjerg, Morten , Pittock, Sean J. , Graus, Francesc , Dalmau, Josep , Schreiner, Bettina , Honnorat, Jérôme , Méneret, Aurélie , Desestret, Virginie , Boucher, Julie, Zéphir, Hélène , Damier, Philippe , Combres, Hélène, Cumin, Marina, Compoint, Mathilde, Chanson, Marine, Vogrig, Alberto , Casez, Olivier , Kalifa, Laurette, Rusu, Elena Camelia, Carra‐Dallière, Clarisse , Cluse, Florent , Brueggemann, Norbert, Seifert‐Held, Thomas , Villacieros‐Álvarez, Javier , Berger–Sieczkowski, Evelyn , Tambasco, Nicola , Nigro, Pasquale , Iorio, Raffaele , Ono, Yoya , Shimohata, Takayoshi , Bastiaansen, Danielle

Mayo Clinic

Brain | July 12, 2025 | Volume: 149 | Issue: 3 | Pages: 884-896

10.1093/brain/awaf256 | PMID 40650880 Get It

Abstract Anti-IgLON5 disease is an autoimmune encephalitis that presents with a heterogenous clinical phenotype, including sleep disorders, movement abnormalities and bulbar involvement. It is characterized by autoantibodies against IgLON5, 85% association with HLA-DQB1*05:∼ and a brainstem-dominant tauopathy. Cellular and murine models report pathogenic effects of the autoantibodies, and neurodegenerative factors suggest progressive atrophy as a common sequela. However, evidence from in vivo patient data and long-term follow-up is limited, and the degree of progression remains elusive. In this multicentre study, clinical and brain MRI data were collected from 127 patients across 12 countries to investigate the relationships between clinical presentations and the development of distinct brain atrophy patterns. Our data show that most patients develop a complex multisystem phenotype as the disease progresses; however, neuromuscular manifestations rarely emerge at later disease stages. By comparison to healthy controls, this disease presents with severe substructure-specific atrophy, especially affecting the hypothalamus, brainstem, accumbens and basal ganglia, which, in age-independent analyses, show significant ventricular enlargement and also suggest progression of brainstem atrophy over the disease course. Moreover, the focality of atrophy was functionally linked to specific symptoms, with more severe involvement of the basal ganglia in patients with movement disorders, and greater atrophy in the hippocampus and thalamus in patients with cognitive impairment. Taken together, our results provide evidence of distinct atrophy patterns in anti-IgLON5 disease, which closely mirror sites of pathophysiologic processes, including autoantibody binding and tau deposition. Our data emphasize the brainstem as the pathophysiological hub of the disease and provide normative data for the incorporation of atrophy measurements into routine clinical assessments and future treatment studies to monitor disease trajectory and evaluate future treatment strategies.
Multicenter evaluation of blood culture contamination and blood cultures practices in US acute care hospitals: time for standardization
Fabre, Valeria , Hsu, Yea‐Jen , Carroll, Karen C. , Salinas, Alejandra , Abbo, Lilian M. , Bower, Chris , Berry, J. Michael, Degnan, Kathleen, Dhaubhadel, Pragya, Dress, Marci, Feeser, Baevin , Fisher, Mark , Flynn, Cynthia E. , Gettler, Erin , Glasser, Laurel J., Johnson, J. Kristie, Karaba, Sara M. , Kubischta, Alyssa, Landrum, B. Mark, Martinez, Marvin, Mermel, Leonard A. , Pepe, Dana , Qasba, Sonia, Rittmann, Barry , Robinson, Evan D. , Rosa, Rossana , Salinas, Jorge , Shah, Aditya , Schrank, Gregory M. , Spivak, Emily S , Stewart, Kathleen O., Wasylyshyn, Anastasia , Virk, Zunaira, Cosgrove, Sara E. , Abbo, Lilian M , Karaba, Sara M , Fabre, Valeria , Milstone, Aaron M. , Berry, Jennifer, Boyd, Sarah, Diekema, Daniel J. , Ford, Bradley , Glasser, Laurel J., Howard‐Anderson, Jessica , Kim, Justin , Mathers, Amy J. , Moehring, Rebekah W. , O’Horo, John C. , Rodriguez‐Nava, Guillermo , Ryder, Jonathan H. , Shelly, Mark , Talbot, Thomas R. , Schooneveld, Trevor Van , Gadala, Avinash

Mayo Clinic

Journal of Clinical Microbiology | July 11, 2025 | Volume: 63 | Issue: 8 | Pages: No page available

10.1128/jcm.00530-25 | PMID 40643261 Get It

ABSTRACT Clinical and Laboratory Standards Institute (CLSI) recommends a blood culture contamination (BCC) threshold of <3%, with ≤1% considered optimal. However, there is not a standardized definition of BCC, and the effect of multiple definitions on BCC rates or what definitions laboratories use remain unknown. We surveyed 52 hospitals and analyzed 362,078 blood cultures (BCx) collected 1 September 2019 to 31 August 2021 from 62 intensive care units (ICUs) and 231 wards from 48 of these hospitals. We calculated and compared BCC rates using the College of American Pathologists (CAP) or CLSI criteria (both utilize a limited number of skin commensals to define BCC) and the comprehensive National Healthcare Safety Network (NHSN) commensal list. We characterized factors associated with BCC and related outcomes (central-line associated bloodstream infection [CLABSI] and vancomycin use). BCC, BCx positivity, and single BCx rates were monitored by 100%, 39%, and 21% of hospitals, respectively. Hospitals used CAP (65%), CLSI (17%), and NHSN (17%) criteria to define BCC. Mean BCC rate by CAP (CAP-BCC) was 1.38% for ICUs and 0.96% for wards. BCC rates remained similar by CLSI criteria but increased when using NHSN list. Sharing BCC data outside of the laboratory, measuring additional BCx quality indicators, and limiting central catheter-drawn BCx were associated with lower BCC rates. BCC was associated with higher CLABSI rates in ICUs. This study demonstrated variability in laboratory practices and opportunities to optimize BCx stewardship. IMPORTANCE Blood culture contamination (BCC) is associated with patient harm and unnecessary use of healthcare resources. BCC thresholds have been established; however, multiple BCC definitions exist. There is limited data on how BCC rates differ depending on the BCC definition used, what definitions laboratories most commonly use, or their approach to other blood cultures (BCx) quality indicators such as single rates or BCx positivity. A cross-sectional multicenter survey and analysis of BCx data from intensive care unit and wards revealed that most laboratories did not track single BCx or BCx positivity rates and that there was variability in how BCC was defined. Additionally, BCC rates were influenced by the definition used. BCC was associated with increased central-line associated bloodstream infection rates.
Lifetime Risk of First Symptomatic ICH or Seizure in Familial Cerebral Cavernous Malformations
Dammann, Philipp , Santos, Alejandro N. , Mavarani, Laven , Chabriat, Hugues , Croft, Jacob , Renteria, Mellisa, Jang, David, Zhang, Jun , Li, Da , Weng, Jiancong , Pilz, Robin A. , Felbor, Ute , Steinberg, Gary K. , Bervini, David , Raabe, Andreas , Rosales, Julieta , Rieß, Christoph , Karadachi, Hannah, Li, Yan , Köhrmann, Martin, Frank, Benedikt , Schmidt, Börge , Overstijns, Manou , Fung, Christian , Zafar, Atif , Nelson, Jeffrey , Zabramski, Joseph M. , Akers, Amy , Kim, Helen , Guey, Stéphanie , Chabriat, Hugues , Herve, Dominique , Zhang, Jun , Weng, Jian-Cong , Rath, Matthias , Steinberg, Gary K , Bervini, David , Rauschenbach, Laurèl , Jabbarli, Ramazan , Beck, Jürgen , Fung, Christian , Al-Shahi Salman, Rustam , Flemming, Kelly D , Lanzino, Giuseppe , Morrison, Leslie , Kim, Helen , Sure, Ulrich , Karadachi, Hanah Hadice , Santos, Alejandro N. , Guey, Stéphanie , Wu, Zhenhua , Petracca, Antonio , Fusco, Carmela , D’Agruma, Leonardo , Castori, Marco , Gu, Jing , Goldberg, Johannes , Cervio, Andrés , Villamil, Facundo , Rauschenbach, Laurèl , Oppong, Marvin Darkwah , Ahmadipour, Yahya , Wrede, Karsten Henning , Jabbarli, Ramazan , Deuschl, Cornelius , Piedade, Guilherme Santos , Wälchli, Thomas , Salman, Rustam Al‐Shahi , Flemming, Kelly D. , Lanzino, Giuseppe , Weinsheimer, Shantel , McCulloch, Charles E. , Sure, Ulrich

Mayo Clinic

Neurology | July 10, 2025 | Volume: 105 | Issue: 3 | Pages: No page available

10.1212/wnl.0000000000213798 | PMID 40638881 Get It

Minimal Clinically Important Difference and Relative Change in Patient-Reported Outcomes After Surgery for Cervical Spondylotic Myelopathy: A Nationwide Study of 1,700 Patients
El-Hajj, Victor Gabriel , Staartjes, Victor E. , Atallah, Elias , Babaei, Darius, Bydon, Mohamad , Elmi‐Terander, Adrian , Elmi-Terander, Adrian , El-Hajj, Victor Gabriel , Staartjes, Victor E , Klukowska, Anita Maria , Gerdhem, Paul , Edström, Erik

Mayo Clinic

Neurosurgery | July 10, 2025 | Volume: 98 | Issue: 2 | Pages: 358-364

10.1227/neu.0000000000003596 | PMID 40637438 Get It

BACKGROUND AND OBJECTIVES: Healthcare policies have seen significant reforms, with a marked transition toward a patient-centered approach. This shift emphasizes the use of subjective patient-reported outcome measures as key metrics. However, these measures often face limitations, particularly in identifying clinically meaningful changes over time. To address this challenge, the concept of the minimal clinically important difference (MCID) was introduced. This study aims to evaluate the predictive effectiveness of relative change and its associated threshold, the minimal clinically important relative change (MCIRC), as a potential alternative to absolute differences and the MCID. METHODS: Data prospectively collected between 2006 and 2021 from the Swedish Spine Registry (Swespine) were analyzed. Patient-reported outcome measures included the Numeric Rating Scale (NRS) for neck and arm pain, the EQ5D index, EQ VAS, and the Neck Disability Index (NDI). Anchor-based methods were used to calculate the MCID and MCIRC. The predictive performance of absolute differences and relative changes was compared using the area under the receiver operating characteristic curve. RESULTS: 1756 patients were included. The selected MCID values were −3 for NRS neck pain intensity, −2 for arm pain intensity, 0.09 for the EQ5D index, 7 for EQ VAS, and −12 for NDI scores. For MCIRC, the chosen values were −47% for NRS neck pain intensity, −40% for arm pain intensity, 386% for the EQ5D index, 52% for EQ VAS, and −32% for NDI scores. On area under the ROC curve, relative change was superior for NRS neck and arm pain scores and NDI, while absolute difference was superior for EQ5D and EQ VAS scores. CONCLUSION: Relative change, along with its associated minimal clinically important value (MCIRC), proved to be a more suitable indicator of subjective satisfaction for NRS and NDI scores. By contrast, absolute differences and the MCID were better suited for evaluating the EQ5D index and EQ VAS scores.
Procedural Characteristics and Outcomes of Transvenous Cardiac Device Extraction in Patients With Left Ventricular Assist Devices
Deering, Thomas F. , Bhimani, Ashish A. , Cole, Robert C., Kella, Danesh K , Kella, Danesh , Cole, Robert C., Goyal, Sandeep

Mayo Clinic

Journal of Cardiovascular Electrophysiology | July 10, 2025 | Volume: 36 | Issue: 9 | Pages: 2160-2164

10.1111/jce.16769 | PMID 40635399 Get It

ABSTRACTIntroductionDurable left ventricular assist devices (LVADs) are susceptible to infection. The presence of a transvenous cardiac implantable electronic device (CIED) may further elevate this risk, making it necessary to remove the CIED system. This report presents the procedural characteristics and outcomes of CIED system extraction in patients with LVADs.MethodsThis is a single‐center retrospective study that included patients with durable LVADs who underwent transvenous CIED extraction at our institution from 2017 to 2023.ResultsTwenty patients with LVAD (HeartMate II = 14; HeartMate III = 6) underwent CIED removal during the study period. The median age was 52.5 (IQR = 42.5–56.5) years, and 7 patients had ischemic cardiomyopathy. Ninety percent (n = 18) of the extractions were due to infection, while 10% (n = 2) were for lead management. Complete removal of all leads was accomplished in 19 patients (95%). Overall, 40 out of 45 leads were removed during 20 procedures. Simple traction was used in 8 patients and specialized extraction tools were used in 12 (laser sheaths = 10; mechanical rotational sheaths = 7; both = 5). No leads were removed in one patient (5 leads; 2 abandoned leads with 42.5 years intravascular dwell time). There were no major procedure‐related complications. Two minor procedure‐related complications included a femoral arterial pseudoaneurysm and one pocket revision due to persistent surgical site bleeding. During a median follow‐up of 17 (IQR = 8.0–22.3) months, 8 patients underwent pump exchange due to persistent infection, and 15 remained on chronic suppressive antibiotics. Nine patients died during the follow‐up.ConclusionThe extraction of CIED systems in patients with LVAD is safe and feasible, exhibiting low procedure‐related morbidity and mortality. However, the long‐term prognosis for these patients remains poor despite the removal of CIEDs.
Real-World Experience with Teclistamab for Relapsed/Refractory Multiple Myeloma from the US Myeloma Immunotherapy Consortium
Razzo, Beatrice M. , Midha, Shonali , Portuguese, Andrew J. , Grajales‐Cruz, Ariel , Corraes, Andre De Menezes Silva , Costello, Patrick , Liu, Yuxin , Sperling, Adam S. , Nadeem, Omar , Dima, Danai , Cowan, Andrew J. , Afrough, Aimaz , Anderson, Larry D. , Goyal, Anmol , Ferreri, Christopher J. , Voorhees, Peter M. , Patel, Krina K. , Julian, Kelley , Forsberg, Peter A. , Susanibar-Adaniya, Sandra P. , Khouri, Jack , Raza, Shahzad , Vazquez‐Martinez, Mariola , Sborov, Douglas W. , Davis, James A. , Shune, Leyla , Bhurtel, Jenny , Hwang, Wei‐Ting , Sidana, Surbhi , Grajales-Cruz, Ariel F , De Menezes Silva Corraes, Andre , Banerjee, Rahul , Cowan, Andrew J , Afrough, Aimaz , Anderson, Larry D , Lieberman-Cribbin, Alex , Kaur, Gurbakhash , Goyal, Anmol , Atrash, Shebli , Ferreri, Christopher , Voorhees, Peter , Pasvolsky, Oren , Lee, Hans C , Patel, Krina , Julian, Kelley L , Forsberg, Peter A , Herr, Megan M. , Chhabra, Saurabh , Parrondo, Ricardo D , Lin, Yi , Chen, Anna , Susanibar-Adaniya, Sandra P , Khouri, Jack , Raza, Shahzad , Anwer, Faiz , Vazquez-Martinez, Mariola A , Castaneda Puglianini, Omar , Sborov, Douglas W , Davis, James A , Rossi, Adriana , Shune, Leyla , Bhurtel, Evguenia , Hwang, Wei-Ting , Hansen, Doris K , Sidana, Surbhi , Garfall, Alfred L , Richard, Shambavi , Nadeem, Omar , Dima, Danai , Sperling, Adam S , Portuguese, Andrew J , Banerjee, Rahul , Kaur, Gurbakhash , Atrash, Shebli , Pasvolsky, Oren , Lee, Hans C. , Chhabra, Saurabh , Lin, Yi , Anwer, Faiz , Puglianini, Omar Castañeda , Rossi, Adriana , Hansen, Doris K. , Garfall, Alfred L. , Richard, Shambavi

Mayo Clinic

Blood Cancer Discovery | July 9, 2025 | Volume: 6 | Issue: 6 | Pages: 561-571

10.1158/2643-3230.bcd-24-0354 | PMID 40629516 Get It

Abstract Teclistamab is an anti-CD3-/B-cell maturation antigen (BCMA) bispecific antibody approved for use in relapsed/refractory multiple myeloma. We undertook a retrospective study of post-approval, real-world outcomes with teclistamab in the US Multiple Myeloma Immunotherapy Consortium. Among 509 patients, 89% would have been ineligible for the MajesTEC-1 trial, primarily due to prior BCMA-directed therapy, cytopenias, or diminished performance status. Cytokine release syndrome occurred in 54% (1.4% grade ≥3) and immune effector cell–associated neurotoxicity syndrome in 11% (2.2% grade ≥3), with no fatal events. Infections occurred in 42% and contributed to death in 5%. Partial response (PR) or better was achieved in 53% and very good PR or better in 45%. With 10.1 months of median follow-up, the estimated median progression-free survival (PFS) was 5.8 months and 12-month overall survival was 61%. Independent predictors of less than very good PR and shorter PFS included BCMA-directed chimeric antigen receptor T-cell therapy in the previous 9 months, high disease burden, lymphopenia, and elevated ferritin. Significance: T cell–engaging bispecific antibodies such as teclistamab represent an important new treatment modality for multiple myeloma and other blood cancers. This study evaluates the real-world safety and efficacy of teclistamab, including its activity in populations not represented in the initial phase I/II study, and identifies clinical variables associated with treatment response. See related commentary by Zweegman et al., p. 542
GLP-1 Receptor Agonist Use Is Associated With Small Intestinal Bacterial Overgrowth and Intestinal Methanogen Overgrowth
Fredrick, Thomas , Ospina-Velasquez, Luis, Fredrick, Thomas W , Damianos, John , Jin, Mauricio F. , Wang, Xiao Jing

Mayo Clinic

Foregut: The Journal of the American Foregut Society | July 9, 2025 | Volume: 5 | Issue: 4 | Pages: 433-437

10.1177/26345161251353437 Get It

Introduction: Glucagon-like peptide-1 (GLP-1) receptor agonists (GLP1RAs) are increasingly used to treat obesity and other metabolic conditions; however, they are known to inhibit gastrointestinal motility. Since gastrointestinal microbial overgrowth (MO) can arise in states of intestinal stasis, we sought to investigate the potential association between GLP1RA use and MO. Methods: We analyzed data from 99 patients prescribed GLP1RAs who subsequently underwent testing for MO via intestinal aspirate culture or glucose or lactulose breath tests. Results: Most patients had diabetes. Among patients who underwent culture, 76.2% tested positive for small intestinal bacterial overgrowth (SIBO) at a threshold of ≥10³ CFU/mL, with a significant association found between proton pump inhibitor (PPI) use and SIBO. At ≥10 5 CFU/mL, 33.3% tested positive for SIBO, and neither PPI use nor surgical history was associated. Breath testing revealed a 30.6% positivity rate for MO, predominantly characterized by intestinal methanogen overgrowth (IMO). There was no association between control of diabetes and positive MO tests. Conclusion: GLP1RA use is associated with SIBO, although diabetes may be a confounder.
Dissecting the biology of gliomagenesis: Evaluating the interaction between IDH tumor mutation and germline variants
Kosel, Matthew , Decker, Paul A. , Kollmeyer, Thomas M. , Shurtz, Anne K., Molinaro, Annette M. , Moassefi, Mana , Wrensch, Margaret , Jenkins, Robert B. , Eckel‐Passow, Jeanette E. , Vaubel, Rachel A, Jenkins, RB , Eckel-Passow, Jeanette E , Kollmeyer, Thomas , Decker, Paul A. , Drucker, Kristen , Molinaro, Annette M. , Conte, Gian Marco , Moassefi, Mana , Erickson, Bradley J. , Wiencke, John K. , Francis, Stephen , Burns, Terry C. , Vaubel, Rachael A. , Lachance, Daniel Honore , Tobin, W. Oliver

Mayo Clinic

Neuro-Oncology Advances | July 8, 2025 | Volume: 7 | Issue: 1 | Pages: No page available

10.1093/noajnl/vdaf147 | PMID 40709013 Get It

Abstract Background The CCDC26 germline variant rs55705857 is causal for development of IDH mutant (IDHmut) adult glioma. However, ~60% of IDHmut patients do not carry the rs55705857 risk allele. We aimed to identify variants associated with developing IDHmut glioma among patients that do not have the rs55705857 risk allele and to further understand development of IDHwt glioma. Methods We used three datasets that included 1216 IDHmut and 1442 IDHwt glioma patients and a case–case design to perform genome-wide association (GWAS) analyses comparing IDHmut versus IDHwt glioma. Analyses were performed overall and stratified by rs55705857 genotype and sex. Multivariable logistic regression and regression trees were used to develop models to predict IDH status using germline variants, age, and contrast enhancement on MRI. Results Three regions were identified comparing IDHmut versus IDHwt: rs55705857 (meta P-value [P] = 1.35 × 10−43), PHLDB1 (rs7125115, P = 3.46 × 10−17), and D2HGDH (rs71430382, P = 2.43 × 10−12). When analyzing only patients that do not have the rs55705857 risk allele, PHLDB1 (rs7125115, P = 1.73 × 10−13) and D2HGDH (rs71430382, P = 8.86 × 10−10) were identified. Among patients who have the rs55705857 risk allele, four variants between ROBO1 and ROBO2 (rs4680975, P = 4.65 × 10−7) increased the likelihood of having an IDHwt tumor. Tumor expression of ROBO1 was associated with rs4680975 genotype in IDHwt patients that have the rs55705857 risk allele (P = 0.034). Multivariable logistic analysis demonstrated that rs55705857, rs71430382 (D2HGDH), and age predicted IDH mutation status. Conclusions To understand the development of adult glioma, we demonstrate that D2HGDH and PHLDB1 should be prioritized for functional studies in IDHmut tumors. The ROBO1 region warrants further investigation in IDHwt tumors.
Exogenous Hormones, Tumor Intrinsic Subtypes, and Breast Cancer
Cornet, Charlotte Le , Truong, Thérèse, Bolla, Manjeet K. , Koutros, Stella, Stone, Jennifer , Shulman, Katerina, Aronson, Kristan J. , Guénel, Pascal, Patel, Alpa V , Bodelón, Clara , Teras, Lauren R., Shahi, Shamim , Dossus, Laure, Kaaks, R., Holleczek, Bernd , Hoppe, Reiner , Czene, Kamila, Hall, P.F., Mannermaa, Arto, Wu, Anna H. , Obi, Nadia , Panayiotidis, Mihalis I. , Haiman, Christopher A., Shu, Xiao , Perou, Charles M. , Alsten, Sarah Van, Eliassen, A. Heather, Kraft, Peter, Ahearn, Thomas U., Evans, D. Gareth , Wolk, Alicja, Easton, Douglas F., Pharoah, Paul D. P., Vachon, Celine M. , Chang-Claude, Jenny, Evans, D Gareth , Perou, Charles M , Stone, Jennifer , Panayiotidis, Mihalis I , Jung, Audrey , Behrens, Sabine , Middha, Pooja , Truong, Thérèse , Jernström, Helena , Wang, Qin , Southey, Melissa C. , Freeman, Laura E. Beane , Koutros, Stella , Rennert, Gad , Murphy, Rachel A. , Guénel, Pascal , Teras, Lauren R. , Lacey, James V. , Dossus, Laure , Kaaks, Rudolf , Brenner, Hermann , Brauch, Hiltrud , Czene, Kamila, Mannermaa, Arto , Michailidou, Kyriaki , McLean, Catriona , Haiman, Christopher A., Augustinsson, Annelie , Zheng, Wei , Troester, Melissa A. , Abubakar, Mustapha , Ahearn, Thomas U., Wolk, Alicja , Milne, Roger L. , Easton, Douglas F. , Schmidt, Marjanka K. , García‐Closas, Montserrat , Vachon, Celine M. , Fortner, Renée T. , Chang‐Claude, Jenny

Mayo Clinic

JAMA Network Open | July 7, 2025 | Volume: 8 | Issue: 7 | Pages: e2519236

10.1001/jamanetworkopen.2025.19236 | PMID 40622713 Get It

ImportanceEtiologic heterogeneity in breast carcinogenesis needs to be well characterized for targeted prevention. Associations between menopausal hormonal therapy (MHT) and oral contraceptive (OC) use and breast cancer intrinsic-like subtypes are not well understood.ObjectiveTo examine whether exogenous hormone use is differentially associated with breast cancer subtypes and to evaluate heterogeneity by intrinsic-like subtypes.Design, Setting, and ParticipantsThis study pooled data from 31 nested and population-based case-control studies involved in the Breast Cancer Association Consortium. The study population included individuals with breast cancer and control participants from 13 case-control studies nested in prospective cohorts (recruited between 1982 and 2011) and 18 population-based case-control studies (recruited between 1990 and 2013). Data analysis was performed in June 2024.ExposureMHT use (estrogen-progestin therapy [EPT] or estrogen-only therapy [ET]) in postmenopausal women and OC use in premenopausal women (never, past use, or current use).Main Outcomes and MeasuresBreast cancer intrinsic-like subtypes (luminal A–like, luminal B–like, luminal B–ERBB2 [formerly HER2 or HER2/neu]-like, ERBB2 enriched–like, or triple-negative) were determined by immunohistochemistry of tumor sections. Polytomous logistic regression was performed to estimate the association between exogenous hormones and risk of breast cancer by intrinsic-like subtypes. Analyses by subtypes were stratified by body mass index (BMI [calculated as weight in kilograms divided by height in meters squared]; healthy weight, 18.5-&amp;lt;25; overweight, 25-&amp;lt;30; or obesity, ≥30).ResultsThis study included 42 269 individuals with breast cancer (11 901 [28.2%] premenopausal and 30 368 [71.8%] postmenopausal; 23 353 [55.2%] had a known intrinsic-like subtype) and 71 072 control participants. The mean (SD) age of all participants was 57.9 (10.9) years. In postmenopausal women, associations between current MHT use (EPT or ET) and breast cancer differed by subtype. Current EPT users with healthy weight were more likely to be diagnosed with luminal A–like (odds ratio [OR], 2.51 [95% CI, 2.26-2.80]) or luminal B–ERBB2-like (OR, 1.95 [95% CI, 1.61-2.37]) subtypes. These associations were attenuated but remained for individuals with overweight (OR, 1.40 [95% CI, 1.02-1.92]) or obesity (OR, 1.68 [95% CI, 1.01-2.78]). EPT use increased the odds of being diagnosed with luminal B–like tumors solely in women with healthy weight (OR, 1.47 [95% CI, 1.17-1.86]). Current ET use was positively associated with luminal A–like disease in women with healthy weight only (OR, 1.16 [95% CI, 1.01-1.32]), showing inverse associations with higher BMI (obesity: OR, 0.65 [95% CI, 0.50-0.85]). In premenopausal women, recent OC use was associated with luminal B–ERBB2-like (OR, 1.50 [95% CI, 1.09-2.08]), ERBB2 enriched–like (OR, 2.33 [95% CI, 1.55-3.51]), and triple-negative (OR, 1.75 [95% CI, 1.33-2.29]; P &amp;lt; .04 for heterogeneity) tumors.Conclusions and RelevanceIn this study, clear differences were observed in associations between current EPT use and luminal-like breast cancer subtypes and other subtypes. EPT users with healthy weight were more likely to be diagnosed with luminal-like breast cancer compared with nonusers. Subtype heterogeneity was less apparent in associations of OC and ET use. Future studies on contemporary formulations, patterns of use, and routes of administration of exogenous hormone usage are warranted.